{"id":303757,"date":"2026-07-13T05:23:23","date_gmt":"2026-07-13T05:23:23","guid":{"rendered":"https:\/\/www.europesays.com\/se\/303757\/"},"modified":"2026-07-13T05:23:23","modified_gmt":"2026-07-13T05:23:23","slug":"leqembi-i-autoinjektor-visade-jamforbar-effekt-och-sakerhet-med-intravenos-formulering","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/303757\/","title":{"rendered":"Leqembi i autoinjektor visade j\u00e4mf\u00f6rbar effekt och s\u00e4kerhet med intraven\u00f6s formulering"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Forskningsbolaget Bioarctics partner Eisai presenterade nya data vid AAIC 2026 som visar att den subkutana autoinjektorversionen av Leqembi gav effekt och s\u00e4kerhet j\u00e4mf\u00f6rbar med den intraven\u00f6sa behandlingen vid tidig Alzheimers sjukdom. En fast dos p\u00e5 500 milligram per vecka uppn\u00e5dde bioekvivalens och likv\u00e4rdig l\u00e4kemedelsexponering oavsett kroppsvikt.\n <\/p>\n<p>Data fr\u00e5n klinisk praxis pekade ocks\u00e5 p\u00e5 bibeh\u00e5llen klinisk nytta och h\u00f6g patient- och v\u00e5rdgivarn\u00f6jdhet, enligt ett pressmeddelande.\n <\/p>\n<p>&#8221;Det subkutana doseringsalternativet kan erbjuda ett bekv\u00e4mt alternativ i hemmet till intraven\u00f6s infusion, med potential att \u00f6ka tillg\u00e5ngen till behandling och m\u00f6jligg\u00f6ra mer flexibel v\u00e5rd inom olika v\u00e5rdmilj\u00f6er&#8221;, skriver Bioarctic.<br \/>\n <br class=\"col-start-2\"\/><\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Amila Ceranic<br \/>\n <br class=\"col-start-2\"\/><br \/>\n Nyhetsbyr\u00e5n Finwire<\/p>\n","protected":false},"excerpt":{"rendered":"Forskningsbolaget Bioarctics partner Eisai presenterade nya data vid AAIC 2026 som visar att den subkutana autoinjektorversionen av Leqembi&hellip;\n","protected":false},"author":2,"featured_media":303758,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[2636,72,70,71,34,31,33,32,30],"class_list":["post-303757","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-bioarctic","tag-business","tag-economy","tag-ekonomi","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116911001133334547","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/303757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=303757"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/303757\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/303758"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=303757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=303757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=303757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}